AstraZeneca PLC AZN NYSE

AstraZeneca PLC (AZN) generated $2.43B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $1.05B, free cash flow was $1.38B.

Free cash flow margin was 8.9% of revenue. Cash conversion ratio was 1.03x, indicating earnings are backed by cash.

The company returned $198.78M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (94/100, Pass) — $1.38B (8.9% margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 1.03x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.